Your institution may have access to this item. Find your institution then sign in to continue.
Title
MARKETPLACE.
Abstract
The article presents drug and therapeutics updates in Canada as of November 2016. It mentions the approval of several drugs including Alecensaro (alectinib) from Hoffmann-La Roche Ltd., Iagrisso (osimertinib) from AstraZeneca Canada Inc., and Empliciti (elotuzumab) from Bristol-Myers Squibb Co. Information on the indication of Opdivo + Yervoy (nivoluniab + ipiliniumab) from Bristol-Myers Squibb is also given.